Loading
NASDAQHealthcareBiotechnology
Latest quote
$23.84
−$0.55 · -2.26%
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Latest quote
$23.84
−$0.55 · -2.26%
After-hours
$23.90
+$0.06 · +0.25%
Sep 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Day range
Current $23.84
52-week range
Current $23.84
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
79
Undervalued
Sentiment
55
Mixed
Risk
43
Elevated Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Day range
Current $23.84
52-week range
Current $23.84
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 376.07M USD | 196.54M USD | 59.61M USD | 3.69M USD | — |
| Cost of goods sold | 36.7M USD | 19.13M USD | 4.99M USD | 754K USD | 763K USD |
| Gross profit | 339.38M USD | 177.41M USD | 54.62M USD | 2.93M USD | −763K USD |
| Research and development | 77.05M USD | 76.42M USD | 110.58M USD | 182.44M USD | 145.56M USD |
| Selling, general, and administrative | 274.55M USD | 229.39M USD | 185.15M USD | 122.12M USD | 60.97M USD |
| Operating expenses | 351.6M USD | 305.81M USD | 295.72M USD | 304.56M USD | 205.77M USD |
| Interest income | — | — | — | — | 173K USD |
| Interest expense | 12.08M USD | 27.17M USD | 29.71M USD | 15.65M USD | — |
| Depreciation and amortization | 5.37M USD | 2.6M USD | 1.88M USD | 1.25M USD | 763K USD |
| Operating income | −12.23M USD | −128.4M USD | −241.1M USD | −301.63M USD | −206.53M USD |
| Net income | −16.14M USD | −140.04M USD | −262.14M USD | −311.46M USD | −206.36M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$38.00
59.40% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI96.17M0.00%2.3T USD0.03%$375.56-0.54%
State Street SPDR S&P Biotech ETFXBI76.39M0.67%11.43B USD0.35%$159.38-1.57%
iShares Russell 2000 ETFIWM69.17M0.09%80.51B USD0.19%$290.64-1.37%
Vanguard Extended Market ETFVXF35.19M0.04%93.7B USD0.05%$238.67-1.11%
iShares Russell 2000 Growth ETFIWO25.15M0.17%14.7B USD0.24%$370.95-1.63%
iShares Biotechnology ETFIBB19.72M0.18%10.73B USD0.44%$205.49-0.89%
Vanguard Russell 2000 ETFVTWO17.25M0.10%17.4B USD0.06%$117.51-1.37%
Schwab U.S. Small-Cap ETFSCHA13.2M0.06%22.86B USD0.03%$34.10-1.04%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
